Skip to main content

Miller Andrew Craig's Form 4 filing

Karuna Therapeutics, Inc. (KRTX) · filed Apr 20, 2023

Accession no.
0000950170-23-013722
Filed
Apr 20, 2023
Trade date
Apr 18-20, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $9.01M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Miller Andrew CraigCIK 0001777760Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 18, 2023Common StockMOption exerciseAcquired+30,000$9.20+$276,00060,900Direct
Apr 18, 2023Common StockSSaleDisposed−30,000$200.16F2−$6,004,80030,900Direct
Apr 20, 2023Common StockMOption exerciseAcquired+8,500$9.20+$78,20039,400Direct
Apr 20, 2023Common StockSSaleDisposed−15,000$200.13−$3,001,95024,400Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 18, 2023Common StockMOption exerciseDisposed−30,000$0.00$0240,492Direct
Apr 20, 2023Common StockMOption exerciseDisposed−8,500$0.00$0231,992Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)